Pfizer & Lilly’s JAK Inhibitors Drug...

Biogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with limited sales and a constraining Medicare coverage plan, the medicine is now facing additional scrutiny as part of a pair...

HPV (Human papillomavirus) is a very commonly found virus and most people have experienced it at some point in their lives. There are almost 200 different strains that can be split into low risk and high risk. Low-risk HPV usually doesn’t cause many problems, it usually causes conditions like genital warts. Whereas...

Insulet Received FDA Clearance for its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control On January 28, 2022, Insulet Corporation, a market leader in developing tubeless insulin pumps with its product, Omnipod®, received the FDA approval for its Omnipod® 5 Automated Insu...

Immunocore Receives FDA Approval for the First Uveal Melanoma Treatment, As Well As the First T-cell Receptor Therapeutics Uveal Melanoma, an aggressive eye cancer, has proven to be a tough nut to crack for researchers seeking a cure. However, with the approval of a new treatment, those with the disorder will ha...

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

Algernon receives positive FDA feedback on Phase IIb chronic cough trial The US Food and Drug Administration (FDA) has given positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) for chronic cough treatment.  A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenp...